PTPN13 and breast carcinoma: Expression of an activated ErbB2 mutant or over-expression of wildtype ErbB2 (as in Her2 breast cancers), together with decreased PTPN13 expression or function, not only enhances complex formation but also leads to EphrinB1 phosphorylation and associated downstream signaling.